多西他赛联合雄激素剥夺和放疗治疗高危局限性前列腺癌:ICECaP个体患者数据荟萃分析
该个体患者数据荟萃分析纳入4项试验的1690例高危局限性前列腺癌患者,评估在放疗和长期雄激素剥夺治疗基础上加用多西他赛的疗效。结果显示多西他赛未显著改善无转移生存或总生存,但显著改善无事件生存和前列腺癌特异性死亡率。
要点
- 多西他赛未显著改善高危局限性前列腺癌患者的无转移生存(HR 0.89)或总生存(HR 0.88)。
- 多西他赛显著改善无事件生存(HR 0.87)和前列腺癌特异性死亡率(HR 0.70)。
- 高危与极高危患者之间多西他赛疗效无显著异质性(所有交互作用P>0.1)。
核心结论
- 在放疗和雄激素剥夺治疗基础上加用多西他赛未显著改善高危局限性前列腺癌患者的无转移生存或总生存。
- 多西他赛显著改善无事件生存和前列腺癌特异性死亡率。
研究设计与样本
- 采用一项个体患者数据荟萃分析,纳入ICECaP数据库中评估放疗+雄激素剥夺治疗±多西他赛的4项试验,共1690例高危局限性前列腺癌患者。
- 高危定义为Gleason评分≥8、前列腺特异性抗原>20 ng/ml、cT3-T4和/或N1中任一危险因素;极高危定义为2-3个危险因素和/或N1。
- 主要终点为无转移生存,次要终点包括总生存、无事件生存、前列腺癌特异性死亡率和至转移时间。
- 采用一阶段个体患者数据荟萃分析,使用多变量Cox比例风险模型和Fine-Gray竞争风险模型估计效应。
主要发现
- 多西他赛未带来无转移生存(HR 0.89)、总生存(HR 0.88)和至转移时间(HR 0.87)的总体获益。
- 多西他赛显著改善无事件生存(HR 0.87)和前列腺癌特异性死亡率(HR 0.70)。
- 放疗+雄激素剥夺治疗组5年和10年无转移生存率分别为79%和57%,加用多西他赛组分别为84%和62%。
- 极高危与高危患者比较多西他赛疗效:无转移生存HR 0.87 vs 0.97,总生存HR 0.86 vs 0.95,无事件生存HR 0.83 vs 0.93,至转移时间HR 0.86 vs 0.92,前列腺癌特异性死亡率HR 0.70 vs 0.73,风险组间交互作用均无统计学显著性(所有p-interaction >0.1)。
临床怎么用
- 对于高危局限性前列腺癌,在放疗和雄激素剥夺治疗基础上加用多西他赛未显示无转移生存或总生存获益,需结合临床分层和生物标志物评估可能获益的患者。
局限性
- 研究纳入的试验数量有限(4项),样本量1690例,可能影响统计效能。
- 高危和极高危亚组分析中多西他赛疗效无显著异质性,但未发现明确获益人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The addition of docetaxel to radiotherapy (RT) and long-term androgen deprivation therapy (ADT) is not a standard of care for the treatment of high-risk localized prostate cancer (HRLPC). We performed an individual patient data (IPD) meta-analysis to assess the addition of docetaxel to RT and ADT in HRLPC. METHODS: IPD from patients with HRLPC (as defined by any of the following risk factors: Gleason score ≥8, prostate-specific antigen >20 ng/ml, cT3-T4, and/or N1) treated in trials evaluating RT + ADT ± docetaxel, available in the Intermediate Clinical Endpoints in Carcinoma of the Prostate (ICECaP) repository, were collated. The primary outcome was metastasis-free survival (MFS), and the secondary outcomes were overall survival (OS), event-free survival (EFS), prostate cancer-specific mortality (PCSM), and time to metastasis (TTM). Analyses were conducted using a one-stage IPD meta-analysis. Disease risk was defined as high (one risk factor) or very high (two to three risk factors and/or N1). Multivariable Cox proportional hazards and Fine-Gray competing risk models estimated the effect of addition of docetaxel to RT + ADT on each time-to-event outcome. KEY FINDINGS AND LIMITATIONS: A total of 1690 patients from four trials were included. Docetaxel did not lead to an overall benefit in MFS (hazard ratio [HR] 0.89), OS (HR 0.88), and TTM (HR 0.87), but there was a significant benefit in EFS (HR 0.87) and PCSM (HR 0.70). The 5- and 10-yr MFS rates were, respectively, 79% and 57% in patients treated with RT + ADT, and 84% and 62% in those who received RT + ADT + docetaxel. There was no clear evidence of a greater benefit of docetaxel in patients with very-high-risk disease than in those with high-risk disease (MFS: HR 0.87 vs 0.97; OS: HR 0.86 vs 0.95; EFS: HR 0.83 vs 0.93; TTM: HR 0.86 vs 0.92; and PCSM: HR 0.70 vs 0.73), with no statistically significant difference in treatment effect by risk group (all p-interaction >0.1). CONCLUSIONS AND CLINICAL IMPLICATIONS: Addition of docetaxel to RT + ADT did not lead to a significant benefit in MFS or OS. Clinical stratification together with biomarkers should be evaluated to determine whether biologic features can identify HRLPC patients who are more likely to benefit from intensification of therapy with docetaxel.
引用
- Ravi P, Kwak L, Xie W, et al. Docetaxel with Androgen Deprivation and Radiotherapy in High-risk Localized Prostate Cancer: An ICECaP Individual Patient Data Meta-analysis. Eur Urol Oncol. 2025. PMID: 41412841. doi:10.1016/j.euo.2025.11.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。